Literature DB >> 15961574

Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy.

Maryam Feili-Hariri1, Dewayne H Falkner, Penelope A Morel.   

Abstract

Dendritic cells (DCs) activate T cells and regulate their differentiation into T helper cell type 1 (Th1) and/or Th2 cells. To identify DCs with differing abilities to direct Th1/Th2 cell differentiation, we cultured mouse bone marrow progenitors in granulocyte macrophage-colony stimulating factor (GM), GM + interleukin (IL)-4, or GM + IL-15 and generated three distinct DC populations. The GM + IL-4 DCs expressed high levels of CD80/CD86 and major histocompatibility complex (MHC) class II and produced low levels of IL-12p70. GM and GM + IL-15 DCs expressed low levels of CD80/CD86 and MHC class II. The GM + IL-15 DCs produced high levels of IL-12p70 and interferon (IFN)-gamma, whereas GM DCs produced only high levels of IL-12p70. Naive T cells stimulated with GM + IL-4 DCs secreted high levels of IL-4 and IL-5 in addition to IFN-gamma. In contrast, the GM + IL-15 DCs induced higher IFN-gamma production by T cells with little or no Th2 cytokines. GM DCs did not induce T cell polarization, despite producing large amounts of IL-12p70 following activation. A similar pattern of T cell activation was observed after in vivo administration of DCs. These data suggest that IL-12p70 production alone, although necessary for Th1 differentiation, is not sufficient to induce Th1 responses. These studies have implications for the use of DC-based vaccines in immunotherapy of cancer and other clinical conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961574     DOI: 10.1189/jlb.1104631

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  48 in total

1.  Lack of IL-15 results in the suboptimal priming of CD4+ T cell response against an intracellular parasite.

Authors:  Crescent L Combe; Magali M Moretto; Joseph D Schwartzman; Jason P Gigley; David J Bzik; Imtiaz A Khan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-13       Impact factor: 11.205

Review 2.  Dendritic cell immunotherapy for autoimmune diabetes.

Authors:  Maryam Feili-Hariri; Rafael R Flores; A Cecilia Vasquez; Penelope A Morel
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  Immune response to biologic scaffold materials.

Authors:  Stephen F Badylak; Thomas W Gilbert
Journal:  Semin Immunol       Date:  2008-02-20       Impact factor: 11.130

Review 4.  Dendritic cells and the maintenance of self-tolerance.

Authors:  Penelope A Morel; Michael S Turner
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 5.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

6.  Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant.

Authors:  Anna U Bielinska; Paul E Makidon; Katarzyna W Janczak; Luz P Blanco; Benjamin Swanson; Douglas M Smith; Tiffany Pham; Zsuzsanna Szabo; Jolanta F Kukowska-Latallo; James R Baker
Journal:  J Immunol       Date:  2014-02-14       Impact factor: 5.422

7.  Differential regulation of interleukin-12 (IL-12)/IL-23 by Tim-3 drives T(H)17 cell development during hepatitis C virus infection.

Authors:  Jia M Wang; Lei Shi; Cheng J Ma; Xiao J Ji; Ruo S Ying; Xiao Y Wu; Ke S Wang; Guangyu Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection.

Authors:  Jia M Wang; Cheng J Ma; Guang Y Li; Xiao Y Wu; Penny Thayer; Pamela Greer; Ashley M Smith; Kevin P High; Jonathan P Moorman; Zhi Q Yao
Journal:  Vaccine       Date:  2013-03-14       Impact factor: 3.641

Review 9.  Gene therapy for brain tumors: basic developments and clinical implementation.

Authors:  Hikmat Assi; Marianela Candolfi; Gregory Baker; Yohei Mineharu; Pedro R Lowenstein; Maria G Castro
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

10.  Oral administration of PPC enhances antigen-specific CD8+ T cell responses while reducing IgE levels in sensitized mice.

Authors:  Mike Burrows; Deepak Assundani; Esteban Celis; Frank Tufaro; Akiko Tanaka; W Guy Bradley
Journal:  BMC Complement Altern Med       Date:  2009-11-30       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.